One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

The findings suggest that while GLP-1 RAs may slightly raise the risk of developing diabetic retinopathy, they do not ...

Many people find GLP-1 agonists beneficial in helping them achieve and maintain a healthy body size, but these medications aren’t perfect, and everyone’s experience is different.

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

GLP-1 receptor agonists, like semaglutide and tirzepatide, are making headlines not just for dramatic weight loss, but also by proving to help target this hormone-driven transformation.

The only safety endpoint associated with GLP-1 receptor agonist use was a 49% increased risk of diabetic retinopathy (aHR, 1.49; 1.11-2.00; P =.008).

For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause mortality than dipeptidyl peptidase-4 inhibitor ...

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl peptidase-4 inhibitors, according to findings scheduled for presentation at ...

GLP-1 receptor agonists may aid smoking cessation by curbing cravings and mitigating weight gain, which often are impediments in quitting, according to a presentation at the American Psychiatric ...

Despite the initial approval of a GLP-1 drug in 2005 and Ozempic's FDA approval in 2017, the market's rapid expansion has largely occurred within the past two years, and it is still evolving.